-
2024-512269-14-00
5
2020-01-27
GIant cell Arteritis
-
2023-508264-29-00
5
2019-06-11
Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
-
2024-512165-13-00
4
2019-05-13
Localised unresectable adenocarcinoma or squamous cell carcinoma of th
-
2024-513207-13-00
4
2019-03-21
oligometastatic hormone sensitive prostate cancer
-
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
-
2023-504951-29-00
5
2017-07-27
Chron's Disease
-
2024-516687-28-00
5
2025-06-06
Patients with GPA and inadequate response to standard of care therapy
-
2024-513648-27-00
4
2024-10-25
Patients with newly or active diffuse Systemic sclerosis (SSc) at the
-
2023-506696-10-00
5
2024-06-18
Non-Small Cell Lung Cancer
-
2023-503576-25-00
5
2023-09-22
Severe Hypertriglyceridemia
-
2022-503022-13-00
5
2023-06-08
Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
-
2022-501420-20-00
5
2023-05-17
Severe hypertryglyceridemia
-
2023-503794-38-00
5
2022-11-24
Prevention of stroke or systemic embolism in atrial fibrillation
-
2024-513653-75-00
5
2022-05-30
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called
-
2024-511263-28-00
6
2022-04-08
Hypercholesterolemia
-
2024-516021-32-00
5
2022-02-17
Critically ill patients suffering from CIRCI
-
2024-515039-31-00
4
2022-02-10
Isatuximab in type I cryoglobulinaemia: A prospective pilot study
-
2024-513532-23-00
5
2021-12-06
early syphilis
-
2023-505894-33-00
4
2020-11-25
Lung Cancer, Non-Small Cell
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-513977-31-00
4
2019-07-17
Untreated squamous cell carcinoma of the head and neck
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2023-505494-32-00
5
2018-10-15
Focal segmental glomerulosclerosis (FSGS)
-
2024-515600-39-00
6
2018-01-23
Adults patients suffering from rheumatoid arthritis and in adequate re